Understanding the Türkiye distribution environment: open to foreign ownership, protective of distributors.
Türkiye is an 86-million-person market with a $1.6 trillion economy and a manufacturing base that exports to Europe. That last point shapes everything. In most categories an imported brand competes with domestic producers whose distributors already sit in every channel, and the strongest distributors have long-standing Turkish principals to protect.
The channel is private-sector-led and polarised. In grocery, hard-discount chains with thousands of stores buy direct and push private label, while corner shops, independent pharmacies and the auto-parts traders of the industrial estates are still served through layers of regional dealers. In healthcare the buyer behind most volume is the state: Social Security Institution reimbursement sets the economics, and public hospitals buy through tenders under the Public Procurement Law.
Foreign ownership is not the obstacle. Foreign Direct Investment Law No. 4875 gives foreign companies national treatment, and there is no Gulf-style commercial agency register. The constraint arrives on exit. Article 122 of the Turkish Commercial Code lets an exclusive distributor claim portfolio compensation when the relationship ends, and any advance waiver is void.
The currency is the other structural fact. Since the 2018 lira crisis, distributors price, stock and extend credit in a currency that loses value inside the payment term, and medicine prices are converted at a state-set euro rate that sits far below the market rate.
Principals underestimate Türkiye because it looks European. The customs union with the EU and CE-harmonised standards suggest an EU distribution template will transfer. It does not: the compensation regime, the dealer layer and the lira each change what a sound agreement looks like.